# ⚔️ PLANNING & MANAGER REVIEWS - MASTER DOCUMENTATION

**Date**: January 28, 2025  
**Status**: ✅ **COMPLETE PLANNING CONSOLIDATION**  
**Consolidated From**: 8 planning/manager review documents (now archived)

---

## 📚 TABLE OF CONTENTS

1. [Executive Summary](#executive-summary)
2. [Master Sources of Truth](#master-sources-of-truth)
3. [Plan Alignment Analysis](#plan-alignment-analysis)
4. [Uncertainties & Risks](#uncertainties--risks)
5. [Testing Infrastructure & Fail-Safes](#testing-infrastructure--fail-safes)
6. [Data Sources Inventory](#data-sources-inventory)
7. [Manager Reviews & Answers](#manager-reviews--answers)
8. [SAE Operational Playbook](#sae-operational-playbook)
9. [Action Items & Next Steps](#action-items--next-steps)

---

## 🎯 EXECUTIVE SUMMARY

### **Planning Status Overview**

This document consolidates all planning documents, manager reviews, and operational guidance for the AYESHA system:

- **Master Sources of Truth**: Comprehensive review plan and uncertainties/risks analysis
- **Plan Alignment**: 85% aligned between comprehensive plan and verification layer
- **Critical Uncertainties**: 5 major uncertainties identified (1 resolved, 1 critical blocker)
- **Manager Reviews**: Complete benchmark review, pathway validation answers, SAE operational playbook
- **Testing Infrastructure**: Comprehensive test coverage and fail-safe mechanisms

### **Key Findings**

1. **Plan Alignment**: 85% aligned - verification layer plan fills critical gap in comprehensive plan
2. **Critical Blocker**: Feature→Pathway Mapping blocks ALL THREE services from using TRUE SAE
3. **Random Weights Resolved**: ✅ Migrated to evo2_7b with trained weights
4. **Manager Policy**: Complete SAE operational playbook with 10 claims (C1-C10) and 5 priorities (P1-P5)

---

## 📋 MASTER SOURCES OF TRUTH

### **1. Comprehensive Review Plan (Scope & Architecture)**

**File**: `.cursor/plans/final-comprehensive-document-review-bad14970.plan.md`

**Purpose**: Complete understanding of SAE & WIWFM integration  
**Focus**: 
- Code execution paths
- Integration points
- Pipeline status
- Proxy vs True SAE distinction
- All three services (Resistance Prophet, Mechanism Fit Ranking, Early Resistance Detection)

**Status**: ✅ **UPDATED** - Proxy vs true SAE clarified, all three services documented

---

### **2. Uncertainties & Risks (Risk Analysis)**

**File**: `.cursor/ayesha/PLAN_UNCERTAINTIES_AND_RISKS.md`

**Purpose**: Critical analysis of uncertainties, gaps, and failure points  
**Focus**:
- What we're unsure about
- What could go wrong
- What's resolved (random weights ✅)
- Critical blockers (Feature→Pathway Mapping ❌)

**Status**: ✅ **UPDATED** - Random weights resolved, all three services documented

---

### **Supporting Documents** (Reference Only)

- **Pipeline Roadmap**: `.cursor/rules/SAE_TO_RESISTANCE_PROPHET_PIPELINE.mdc`
- **Reality Check**: `.cursor/ayesha/BLOG_REALITY_CHECK.md`
- **Resolution Plan**: `.cursor/ayesha/UNCERTAINTIES_RESOLUTION_PLAN.md`
- **Iteration Additions**: `.cursor/ayesha/PLAN_ITERATION_ADDITIONS.md`

---

## 🔍 PLAN ALIGNMENT ANALYSIS

### **Overall Alignment**: **85% ALIGNED** ✅

**Status**:
- ✅ **Analysis Scripts**: Complete (run_mbd4_tp53_analysis.py, answer_mbd4_clinical_questions.py)
- ⚠️ **Verification Layer**: Planned but not implemented (NEW requirement)
- ⚠️ **Validation Assessment**: Planned but not implemented
- ⚠️ **v1 Results Documentation**: Planned but not implemented

**Key Finding**: The verification layer plan **FILLS A CRITICAL GAP** in the comprehensive plan. Phase 13 focuses on running analysis and answering questions, but doesn't include systematic verification of those answers.

---

### **Phase 13: Proxy SAE Validation & MBD4+TP53 Analysis**

#### **Task 13.2.1: Run Complete Analysis Pipeline** ✅ **COMPLETE**

**Plan Requirement**:
- File: `scripts/sae/run_mbd4_tp53_analysis.py` (NEW)
- Steps: Call efficacy/predict, extract pathway scores, call SAE compute_features, call trials/search, call resistance services

**Current Status**: ✅ **IMPLEMENTED**
- File exists: `scripts/sae/run_mbd4_tp53_analysis.py`
- All API endpoints called
- Complete analysis JSON generated

**Alignment**: **100%** ✅

---

#### **Task 13.2.2: Answer 8 Clinical Questions** ✅ **COMPLETE**

**Plan Requirement**:
- File: `scripts/sae/answer_mbd4_clinical_questions.py` (NEW)
- Extract structured answers to all 8 questions

**Current Status**: ✅ **IMPLEMENTED**
- File exists: `scripts/sae/answer_mbd4_clinical_questions.py`
- All 8 questions answered
- Structured JSON output

**Alignment**: **100%** ✅

---

#### **Task 13.3: Proxy SAE Validation Assessment** ⚠️ **PARTIALLY PLANNED**

**Plan Requirement**:
- Task 13.3.1: Assess Current Validation State
- Task 13.3.2: Create Validation Test Suite
- Task 13.3.3: Create Benchmark Dataset
- Task 13.3.4: Run Benchmark Validation

**Current Status**: ⚠️ **PLANNED BUT NOT IMPLEMENTED**
- No validation assessment document exists
- No validation test suite exists
- No benchmark dataset exists
- No benchmark validation script exists

**Gap Identified**: The comprehensive plan mentions validation but doesn't specify **HOW** to verify the answers are correct.

**Verification Layer Plan Contribution**: ✅ **FILLS THIS GAP**
- Phase 1: Deterministic Verification (ClinVar, COSMIC, KEGG, Reactome, FDA, NCCN)
- Phase 2: Formula & Consistency Verification (DNA repair capacity, mechanism vectors)
- Phase 3: Biological Plausibility Verification (expected ranges)
- Phase 4: Integration & Automation (unified verification script)

**Alignment**: **60%** ⚠️ (Plan exists, implementation needed)

---

#### **Task 13.4: Document v1 Results** ⚠️ **PLANNED BUT NOT IMPLEMENTED**

**Plan Requirement**:
- Task 13.4.1: Create Analysis Results Document
- Task 13.4.2: Create Capability Matrix

**Current Status**: ⚠️ **NOT IMPLEMENTED**
- No results document exists
- No capability matrix exists

**Alignment**: **0%** ❌ (Not started)

---

### **Implementation Status Matrix**

| Task | Comprehensive Plan | Verification Plan | Current Status | Alignment |
|------|-------------------|------------------|----------------|-----------|
| **Analysis Pipeline** | Task 13.2.1 | N/A | ✅ Implemented | 100% ✅ |
| **Answer Questions** | Task 13.2.2 | N/A | ✅ Implemented | 100% ✅ |
| **Variant Verification** | Not specified | Phase 1, Task 1.1 | ❌ Not implemented | NEW ✅ |
| **Pathway Verification** | Not specified | Phase 1, Task 1.2 | ❌ Not implemented | NEW ✅ |
| **Functional Verification** | Not specified | Phase 1, Task 1.3 | ❌ Not implemented | NEW ✅ |
| **Eligibility Verification** | Not specified | Phase 1, Task 1.4 | ❌ Not implemented | NEW ✅ |
| **Formula Verification** | Mentioned | Phase 2, Task 2.1 | ❌ Not implemented | NEW ✅ |
| **Mechanism Vector Verification** | Mentioned | Phase 2, Task 2.2 | ❌ Not implemented | NEW ✅ |
| **Consistency Checks** | Not specified | Phase 2, Task 2.3 | ❌ Not implemented | NEW ✅ |
| **Plausibility Checks** | Mentioned | Phase 3, Task 3.1 | ❌ Not implemented | NEW ✅ |
| **Unified Verification** | Not specified | Phase 4, Task 4.1 | ❌ Not implemented | NEW ✅ |
| **Validation Assessment** | Task 13.3.1 | N/A | ❌ Not implemented | 0% ❌ |
| **Validation Test Suite** | Task 13.3.2 | N/A | ❌ Not implemented | 0% ❌ |
| **Benchmark Dataset** | Task 13.3.3 | N/A | ❌ Not implemented | 0% ❌ |
| **Benchmark Validation** | Task 13.3.4 | N/A | ❌ Not implemented | 0% ❌ |
| **v1 Results Document** | Task 13.4.1 | N/A | ❌ Not implemented | 0% ❌ |
| **Capability Matrix** | Task 13.4.2 | N/A | ❌ Not implemented | 0% ❌ |

**Summary**:
- ✅ **Analysis & Question Answering**: 100% complete
- ⚠️ **Verification Layer**: 0% complete (planned, not implemented)
- ❌ **Validation Assessment**: 0% complete (planned, not implemented)
- ❌ **v1 Results Documentation**: 0% complete (planned, not implemented)

---

### **Recommended Integration Strategy**

**Option 1: Sequential Implementation** (Recommended)

**Phase 1: Complete Analysis & Verification** (Week 1-2)
1. ✅ Analysis scripts already complete
2. Implement verification layer (P0 tasks from verification plan)
3. Run analysis with verification
4. Generate verification report

**Phase 2: Validation Assessment** (Week 3)
1. Implement Task 13.3.1-13.3.4 (validation assessment)
2. Create benchmark dataset
3. Run benchmark validation

**Phase 3: Documentation** (Week 4)
1. Implement Task 13.4.1-13.4.2 (v1 results documentation)
2. Create capability matrix
3. Document S/P/E integration status

---

## 🚨 UNCERTAINTIES & RISKS

### **Critical Uncertainties**

#### **Uncertainty 1: Will Biomarker Analysis Find Significant Features?**

**What We Think We Know**:
- Service is complete, bug is fixed
- 66 patients with SAE features extracted
- Outcome field should be populated

**What We're Unsure About**:
- ❓ **Will re-run actually find significant features?** (Previous run found 0)
- ❓ **Are the SAE features meaningful?** (Now using trained weights - evo2_7b migration complete ✅)
- ❓ **Is 66 patients enough for statistical power?** (May need more)
- ❓ **What if outcome distribution is imbalanced?** (53 sensitive, 11 refractory, 2 resistant)

**Potential Failure**:
- Re-run finds 0 significant features again
- All correlations are weak (r < 0.3)
- Statistical tests fail (p > 0.05 after FDR correction)

**Verification Status**:
- [x] Check outcome field is actually populated - **VERIFIED**: All 66 patients have outcome
- [x] Verify feature indices are valid (0-32767) - **VERIFIED**: All indices valid
- [x] Check if SAE weights are trained (not random) - **VERIFIED**: Migrated to evo2_7b, trained weights loaded ✅
- [ ] Check feature distributions (mean, std, variation) - **PENDING**
- [ ] Determine minimum sample size needed - **PENDING**

---

#### **Uncertainty 2: Can We Create Feature→Pathway Mapping Without Biological Validation?** ❌ **CRITICAL BLOCKER**

**Status**: ❌ **CRITICAL BLOCKER** - Blocks ALL THREE services from using TRUE SAE features

**What We Think We Know**:
- Need to map 32K SAE features → 7D pathway scores
- Template exists: `api/resources/sae_feature_mapping_template.json`
- Loader exists: `api/services/sae_feature_service.py:286-307`
- **Impact**: Blocks Resistance Prophet, Mechanism Fit Ranking, and Early Resistance Detection from using TRUE SAE

**What We're Unsure About**:
- ❓ **How do we know which features map to which pathways?** (No biological annotation)
- ❓ **Can we infer pathway mapping from biomarker analysis?** (Biomarker-driven approach - pending analysis)
- ❓ **What if features are multi-pathway?** (One feature might activate DDR + MAPK)
- ❓ **How do we validate the mapping is correct?** (No ground truth, but can test on known cases)

**Approach** (Updated):
- **Biomarker-driven mapping**: Use top significant features from biomarker analysis
- **Gene→pathway inference**: Map features that activate for specific genes to pathways
- **Validation strategy**: Test on known cases (BRCA1 → DDR high, KRAS → MAPK high)
- **Roadmap**: `.cursor/rules/SAE_TO_RESISTANCE_PROPHET_PIPELINE.mdc` (Stage 3-4)

**Potential Failure**:
- Manual annotation is guesswork (no biological basis)
- Mapping doesn't improve pathway scores vs proxy
- Features don't correlate with expected pathways
- Validation fails (pathway scores don't match known biology)

**Services Affected**: ALL THREE services blocked from using TRUE SAE:
- Resistance Prophet: Cannot use TRUE SAE DNA repair capacity
- Mechanism Fit Ranking: Cannot use TRUE SAE mechanism vector
- Early Resistance Detection: Cannot use TRUE SAE DNA repair capacity

**Current Workaround**: All three services use PROXY features (gene mutations → pathway scores)

---

#### **Uncertainty 3: Are SAE Weights Producing Meaningful Features?** ✅ **RESOLVED**

**Status**: ✅ **RESOLVED** - Migrated to evo2_7b with trained weights

**What We Know Now**:
- ✅ SAE service uses **trained weights** (not random) - evo2_7b migration complete
- ✅ Dimension match: 4096-dim Evo2 7B matches 4096-dim checkpoint
- ✅ Trained weights loaded: `Goodfire/Evo-2-Layer-26-Mixed` checkpoint
- ✅ 66 patients extracted with trained weights
- ✅ Feature extraction operational

**What We're Still Unsure About**:
- ❓ **Do trained weights produce meaningful biological signal?** (Need biomarker analysis to verify)
- ❓ **Can we trust biomarker correlations from trained features?** (Need validation)
- ❓ **Will pathway mapping work with trained features?** (Still blocked by mapping creation)
- ❓ **What's the actual impact vs proxy features?** (Need comparison after mapping created)

---

#### **Uncertainty 4: Will Modal SAE Service Work Reliably?** ✅ **MOSTLY RESOLVED**

**What We Know Now**:
- ✅ Modal service is deployed: `src/services/sae_service/main.py`
- ✅ Circuit breaker implemented (lines 238-257)
- ✅ Error handling exists
- ✅ Service operational: 66 patients extracted successfully
- ✅ Trained weights loaded: evo2_7b migration complete

**What We're Still Unsure About**:
- ❓ **Are API keys configured correctly in production?** (Previous 403 errors documented, but extraction succeeded)
- ❓ **Will circuit breaker prevent all failures?** (May reject valid requests)
- ❓ **What happens on timeout?** (May silently fail)

---

#### **Uncertainty 5: How Do We Validate the Entire Pipeline End-to-End?**

**What We Think We Know**:
- Individual components tested (unit tests exist)
- Validation scripts exist (`validate_sae_tcga.py`)
- E2E tests exist (`test_ayesha_post_ngs_e2e.py`)

**What We're Unsure About**:
- ❓ **Do tests cover all failure modes?** (May miss edge cases)
- ❓ **What's the ground truth for validation?** (HRD scores? Clinical outcomes?)
- ❓ **How do we know if pipeline is working correctly?** (No gold standard)
- ❓ **What if validation fails?** (No clear remediation path)

---

### **Potential Failure Points**

#### **Failure Point 1: Biomarker Analysis Finds No Significant Features**

**Probability**: Medium  
**Impact**: High  
**Scenario**: Re-run analysis, still finds 0 significant features

**Possible Causes**:
1. ~~Random SAE weights produce no biological signal~~ ✅ **RESOLVED**: Using trained weights
2. Sample size too small (66 patients insufficient)
3. ~~Outcome field still not populated correctly~~ ✅ **VERIFIED**: All 66 patients have outcome
4. ~~Feature indices still invalid~~ ✅ **VERIFIED**: All indices valid (0-32767)
5. Statistical thresholds too strict
6. Trained SAE features still don't correlate with outcomes (biological signal weak)

**Mitigation**:
- ✅ Data quality verified (outcome field, feature indices)
- ✅ Trained weights loaded (evo2_7b migration complete)
- Consider relaxing statistical thresholds if needed
- May need more patients if signal is weak
- Re-run analysis with trained features to assess biological signal

---

#### **Failure Point 2: Feature→Pathway Mapping Is Biologically Invalid** ❌ **CRITICAL BLOCKER**

**Probability**: High  
**Impact**: High  
**Scenario**: Biomarker-driven mapping creates incorrect pathway assignments

**Services Affected**: ALL THREE services blocked from using TRUE SAE:
- Resistance Prophet: Cannot use TRUE SAE DNA repair capacity
- Mechanism Fit Ranking: Cannot use TRUE SAE mechanism vector
- Early Resistance Detection: Cannot use TRUE SAE DNA repair capacity

**Possible Causes**:
1. No biological basis for mapping (pure guesswork)
2. Features are multi-pathway (can't map to single pathway)
3. Features don't correlate with genes (SAE features are abstract)
4. Validation fails (pathway scores don't match known biology)

**Mitigation**:
- Use biomarker-driven approach (top significant features from analysis)
- Use gene→pathway mapping to infer feature→pathway (for features that activate with specific genes)
- Validate each mapping against literature
- Test on known cases (BRCA1 → DDR high, KRAS → MAPK high, HER2 → HER2 high)
- Compare SAE pathway scores vs proxy pathway scores (should be similar for known cases)
- May need domain expert review
- Roadmap: `.cursor/rules/SAE_TO_RESISTANCE_PROPHET_PIPELINE.mdc` (Stage 3-4)

---

### **Risk Assessment**

**Highest Risk**: Feature→Pathway Mapping (High probability, High impact) ❌ **CRITICAL BLOCKER**
- Blocks ALL THREE services from using TRUE SAE features
- No biological basis for mapping (biomarker-driven approach pending)
- May create incorrect pathway scores
- Could invalidate entire pipeline
- **Current Workaround**: All three services use PROXY features (gene mutations → pathway scores)

**Medium Risk**: Biomarker Analysis (Medium probability, High impact)
- May find 0 significant features (even with trained weights)
- Trained weights should improve signal (but not guaranteed)
- Could block entire pipeline if no significant features found

**Low Risk**: Modal Service (Medium probability, Medium impact)
- Deployment issues are fixable
- Error handling can be improved
- Circuit breaker can be adjusted

---

## ✅ TESTING INFRASTRUCTURE & FAIL-SAFES

### **Existing Test Infrastructure**

**Test Files Identified**:
- `tests/test_sae_phase2_services.py` (530 lines) - Comprehensive SAE Phase 2 test suite
- `scripts/validate_sae_tcga.py` (532 lines) - TCGA validation script
- `scripts/validate_resistance_prophet.py` - Resistance Prophet validation
- `tests/test_ayesha_post_ngs_e2e.py` - End-to-end post-NGS tests
- `tests/test_mechanism_fit_ranker.py` - Mechanism fit ranking tests

**Test Coverage**:
- ✅ SAE Feature Service: DNA repair capacity formula, essentiality, exon disruption
- ✅ Mechanism Fit Ranker: Cosine similarity, L2 normalization, threshold filtering
- ✅ Resistance Detection: 2-of-3 trigger rule, HRD drop detection
- ✅ E2E Integration: Complete care plan with SAE features

---

### **Testing Strategy to Prevent Deviation**

**Unit Tests** (Prevent Logic Errors):
- **Location**: `tests/test_sae_phase2_services.py`
- **Coverage**: All Manager-approved formulas (C1-C10)
- **Validation**: Assert exact formula values (e.g., DNA repair = 0.6×DDR + 0.2×ess + 0.2×exon)
- **Frequency**: Run before every commit

**Integration Tests** (Prevent Integration Errors):
- **Location**: `tests/test_ayesha_post_ngs_e2e.py`
- **Coverage**: Full pipeline from tumor_context → SAE features → resistance detection
- **Validation**: SAE features present, mechanism vector computed, resistance alerts triggered
- **Frequency**: Run before deployment

**Validation Tests** (Prevent Data Quality Issues):
- **Location**: `scripts/validate_sae_tcga.py`
- **Coverage**: SAE features correlate with ground truth (HRD scores)
- **Metrics**: AUROC, AUPRC, sensitivity, specificity
- **Frequency**: Run after data updates

**Regression Tests** (Prevent Breaking Changes):
- **Location**: All test files
- **Coverage**: Previous bug fixes (feature index bug, outcome field bug)
- **Validation**: Known good cases still pass
- **Frequency**: Run in CI/CD pipeline

---

### **Validation Checkpoints**

**Checkpoint 1: Formula Validation**
- **Test**: `test_dna_repair_capacity_formula()` in `test_sae_phase2_services.py`
- **Validates**: Manager's C1 formula (0.6×DDR + 0.2×ess + 0.2×exon)
- **Failure Action**: Block commit, alert manager

**Checkpoint 2: Data Quality Validation**
- **Test**: `validate_sae_tcga.py` - Check outcome distribution
- **Validates**: Outcome field populated, feature indices valid (0-32767)
- **Failure Action**: Block analysis, fix data

**Checkpoint 3: Integration Validation**
- **Test**: `test_ayesha_post_ngs_e2e.py` - Full pipeline test
- **Validates**: SAE features computed, mechanism vector present, resistance detection works
- **Failure Action**: Block deployment, fix integration

**Checkpoint 4: Statistical Validation**
- **Test**: `analyze_biomarkers.py` - Statistical significance
- **Validates**: p < 0.05 (FDR-corrected), Cohen's d >= 0.3
- **Failure Action**: Review results, adjust thresholds if needed

---

### **Fail-Safe Mechanisms to Prevent Hallucinations**

**Code-First Validation**:
- **Principle**: Never assume - always verify with code
- **Implementation**:
  1. Code References Required: Every claim must have code file + line number
  2. Execution Path Tracing: Follow code from entry point to output
  3. Integration Point Verification: Verify service connections with actual code
  4. Data Source Verification: Check data files exist and are accessible

**Data Validation Checkpoints**:
- **Checkpoint 1: File Existence** - Verify data files exist before analysis
- **Checkpoint 2: Data Structure Validation** - Validate JSON structure before processing
- **Checkpoint 3: Outcome Field Validation** - Verify outcome field populated before correlation
- **Checkpoint 4: Feature Index Validation** - Verify indices in valid range (0-32767)

**Formula Validation**:
- **Manager-Approved Formulas** (Must Match Exactly):
  - DNA Repair Capacity: `0.6×DDR + 0.2×ess + 0.2×exon`
  - Mechanism Fit: `0.7×eligibility + 0.3×mechanism_fit`
  - Resistance Detection: 2-of-3 trigger rule
- **Validation**: Unit tests assert exact formula values
- **Failure**: Block commit, alert manager

**Anti-Hallucination Rules**:
1. **Code References Required**: Every claim must cite code file + line
2. **No Assumptions**: Verify with code, don't assume
3. **Data Validation First**: Validate data before processing
4. **Test-Driven Validation**: Write tests for all formulas and logic
5. **Fail Gracefully**: Never crash, always provide partial results

---

## 📊 DATA SOURCES INVENTORY

### **Data Sources We Have (Operational)**

**Source 1: Evo2 Sequence Scoring** ✅
- **Endpoint**: `/api/evo/score_variant_multi`
- **Provides**: Delta scores, calibrated percentiles
- **SAE Feature**: Exon disruption
- **Status**: Operational

**Source 2: Insights Bundle** ✅
- **Endpoints**: `/api/insights/predict_*` (4 endpoints)
- **Provides**: Functionality, chromatin, essentiality, regulatory scores
- **SAE Feature**: Essentiality signal
- **Status**: Operational

**Source 3: Pathway Disruption** ✅
- **Service**: `api/services/pathway/aggregation.py`
- **Provides**: Gene→pathway mapping, pathway burden
- **SAE Feature**: DNA repair capacity
- **Status**: Operational

**Source 4: AlphaMissense Fusion** ✅
- **Endpoint**: `/api/fusion/score_variant`
- **Provides**: Missense pathogenicity scores
- **SAE Feature**: Hotspot mutation detection
- **Status**: Operational

**Source 5: ClinVar Priors** ✅
- **Endpoint**: `/api/evidence/clinvar`
- **Provides**: Pathogenic/Benign classification
- **SAE Feature**: Hotspot mutation (fallback)
- **Status**: Operational

**Source 6: TCGA-OV Cohort Data** ✅
- **File**: `data/validation/sae_cohort/sae_features_tcga_ov_platinum.json`
- **Provides**: 66 patients, 2,897 variants with SAE features
- **Status**: Extracted, ready for biomarker analysis

---

### **Data Sources We're Missing**

**Missing 1: Cohort Signals (Real-World Validation)** ⚠️
- **Planned Endpoint**: `/api/datasets/extract_and_benchmark`
- **Provides**: Cohort coverage, response rates, outcome data
- **SAE Feature**: Cohort overlap
- **Status**: Stub (future, Week 2)
- **Impact**: Cannot validate against real-world outcomes yet

**Missing 2: Feature→Pathway Mapping Table** ❌
- **Expected File**: `api/resources/sae_feature_mapping.json`
- **Provides**: Maps 32K SAE features → 7D pathway scores
- **Status**: Not implemented (critical blocker)
- **Impact**: Cannot use TRUE SAE features for pathway scoring

**Missing 3: Validated Biomarker Results** ⚠️
- **Expected File**: `data/validation/sae_cohort/sae_tcga_ov_platinum_biomarkers.json`
- **Provides**: Top significant features with correlations
- **Status**: Needs re-run (bug fixed, analysis invalid)
- **Impact**: Cannot identify which SAE features are predictive

**Missing 4: HRD Scores for TCGA-OV** ⚠️
- **Expected**: HRD scores (0-100) for validation cohort
- **Status**: Jr2 assigned but not executed
- **Impact**: Cannot validate DNA repair capacity formula

---

## 👔 MANAGER REVIEWS & ANSWERS

### **Manager Benchmark Review**

**Date**: January 27, 2025  
**Status**: ⚠️ **CRITICAL ISSUES IDENTIFIED** - Requires Immediate Action Plan

**Bottom Line**: We have a **working system with excellent drug ranking (100% Top-5)** but **weak predictive accuracy for outcomes**. This is a **critical gap** that must be addressed before production deployment.

**Key Metrics**:

| Metric | Status | Performance | Priority |
|--------|-------|-------------|----------|
| **Drug Ranking** | ✅ Excellent | 100% Top-5 accuracy | Low (working) |
| **PFS Correlation** | ⚠️ Critical | r=0.047 (negligible) | **P0 - BLOCKER** |
| **OS Correlation** | ⚠️ Critical | r=0.198 (weak) | **P0 - BLOCKER** |
| **Classification** | ❌ Cannot Assess | 0 events (parsing issue) | **P0 - BLOCKER** |

**Verdict**: **System is NOT ready for production** until correlation issues are resolved.

**Strategic Recommendations**:

**Priority 0: Fix Classification Assessment (BLOCKER)**
- Inspect PFS_STATUS field format in dataset
- Check PFS_STATUS parsing logic in classification function
- Fix parsing bug (0 events AND 0 censored = impossible)
- **Timeline**: 2 days

**Priority 1: Investigate Weak Correlations (CRITICAL)**
- Run 50-100 patient test with **random sampling** (not just lowest mutations)
- Compare correlation with vs without TMB/HRD/MSI features
- Check if treatment type affects correlation
- **Timeline**: 2 weeks
- **Success Criteria**: Correlations improve to r > 0.3 (moderate) OR we understand why correlations are weak and have mitigation plan

**Priority 2: Complete 50-Patient Test**
- Install lifelines package: `pip install lifelines`
- Run 50-patient test with random sampling
- Validate survival metrics compute correctly
- **Timeline**: 3 days

**Root Cause Analysis**:

**Hypothesis 1: Sample Size Too Small** (Most Likely)
- 10-20 patients = low statistical power
- Need 50-100+ for robust statistics
- **Action**: Run larger test immediately

**Hypothesis 2: Validation Set Bias** (Likely)
- Lowest mutation counts may not represent typical patients
- Low-mutation patients may have different outcomes
- **Action**: Test with random/stratified sample

**Hypothesis 3: Missing Features** (Possible)
- TMB, HRD, MSI not included in predictions
- These are critical for ovarian cancer outcomes
- **Action**: Include biomarker features in predictions

**Success Criteria for Production Readiness**:

**Must Have (Blockers)**:
1. ✅ **Classification Assessment**: Metrics compute correctly with progression events
2. ✅ **Correlation Improvement**: PFS/OS correlations improve to r > 0.3 (moderate) OR we understand why they're weak and have mitigation plan
3. ✅ **Survival Analysis**: 50-patient test completed, survival metrics validated
4. ✅ **Representative Sampling**: Test with random/stratified sample (not just lowest mutations)

**Recommendation**: **DO NOT DEPLOY TO PRODUCTION** until:
1. Classification assessment is fixed
2. Correlations improve to r > 0.3 OR we understand why they're weak and have mitigation plan
3. Representative sampling validates results

---

### **Manager Answers Review - Pathway Validation Roadmap**

**Date**: January 28, 2025  
**Status**: ✅ **ALL ANSWERS CLEAR & ACTIONABLE** - Ready for immediate execution

**All 7 critical questions have been answered with clear, actionable decisions.** The roadmap is **unblocked** and ready for Phase 1 Day 1 execution.

**Key Decisions Confirmed**:
- ✅ Use 469-patient dataset as primary (Q1)
- ✅ Map existing response data (Q2)
- ✅ Acquire HRD scores from publications (Q3)
- ✅ Compute TMB from mutations (Q4)
- ✅ Complete ovarian cancer FIRST (Q5)
- ✅ Use public cBioPortal API (Q6)
- ✅ Focus on TCGA/cBioPortal, defer trial data (Q7)

**Answer Quality Score**: ⭐⭐⭐⭐⭐ **5/5**

**All 7 answers are**:
- ✅ **Clear**: No ambiguity in decisions
- ✅ **Actionable**: Specific tasks and timelines provided
- ✅ **Complete**: Rationale, code, and actions included
- ✅ **Risk-Aware**: Fallbacks and mitigations defined

**Execution Readiness**: ✅ **100% READY**

**Day 1 Tasks** (90 minutes):
1. **TMB Computation** (30 minutes)
   - Create script: `scripts/data_acquisition/compute_tmb.py`
   - Implement formula: `tmb = num_mutations / 38.0`
   - Add `tmb_score` to all 469 patients
   - Categorize: TMB-Low (<6), TMB-Intermediate (6-10), TMB-High (≥10)

2. **Response Format Standardization** (30 minutes)
   - Create script: `scripts/data_acquisition/standardize_response.py`
   - Implement mapping function (from Q2 answer)
   - Transform all 469 patients to required schema

3. **Field Renaming** (15 minutes)
   - Rename `tcga_patient_id` → `patient_id`
   - Rename `tcga_sample_id` → `sample_id`

4. **Output Generation** (15 minutes)
   - Generate final JSON: `data/validation/tcga_ov_469_validated.json`
   - Include summary statistics and provenance

**Day 2 Tasks**:
- HRD acquisition from publications (Marquard et al. paper, cBioPortal, Genomic Scar Scores)
- Patient matching by patient_id
- Coverage check (<80% threshold → fallback to computation)

**Day 3 Tasks**:
- Pathway validation
- Report generation
- Signal confirmation (MAPK/NF1 already validated)

---

### **Manager Review Package - AYESHA System Mastery**

**Date**: January 15, 2025  
**Status**: ✅ **READY FOR MANAGER REVIEW**

**Deliverable Package**:

1. **Complete Capability Map** (`PHASE4_MASTERY_SYNTHESIS.md`)
   - All backend services mapped with file locations
   - All integration points documented
   - Complete data flow diagrams
   - Confidence calculation formulas verified

2. **Integration Flow Diagrams** (`PHASE2_INTEGRATION_ANALYSIS.md`)
   - S/P/E → SAE data flow (with code references)
   - SAE → Confidence flow (gap identified)
   - Ayesha orchestrator end-to-end flow
   - Integration status matrix

3. **Validated Gap List** (`PHASE3_GAP_ANALYSIS_COMPLETE.md`)
   - 3 gaps identified with code evidence
   - No assumptions - all gaps validated
   - Prioritization matrix (P0/P1/P2)

4. **Formula Verification Report** (`PHASE5_ANTI_HALLUCINATION_VALIDATION.md`)
   - S/P/E Formula: Exact match (docs vs. code)
   - Confidence Formula (V1): Exact match
   - SAE DNA Repair Capacity: Exact match

5. **Execution Path Traces** (`PHASE5_ANTI_HALLUCINATION_VALIDATION.md`)
   - Ayesha Pre-NGS Care (5 steps, all verified)
   - Post-NGS Drug Prediction (8 steps, all verified)
   - Resistance Detection (5 steps, all verified)

**Key Findings**:

**✅ Operational Capabilities**:
1. **S/P/E Framework**: ✅ Complete, battle-tested
2. **Ayesha Orchestrator v2**: ✅ Fully operational (706 lines)
3. **CA-125 Intelligence**: ✅ Production-ready (702 lines)
4. **Resistance Playbook V1**: ✅ 19/19 tests passing
5. **Resistance Prophet**: ✅ Complete, integrated
6. **SAE Feature Extraction**: ✅ Complete (display only)

**❌ Critical Gaps**:
1. **SAE→WIWFM Integration**: ❌ NOT DONE
   - **Status**: SAE extracted but not modulating confidence
   - **Blocking**: Manager policy approval + validation
   - **Priority**: P0 (Critical)

2. **SAE Biomarker Analysis**: ⏸️ BLOCKED
   - **Status**: Service built, Modal not deployed
   - **Blocking**: H100 GPU deployment
   - **Priority**: P1 (High Value)

**Mastery Metrics**:
- Documentation Reviewed: 13+ major documents
- Code Files Reviewed: 15+ critical files
- Integration Points Mapped: 10+ integration points
- Gaps Identified: 3 (all validated with code evidence)
- Formulas Verified: 3 (all exact matches)
- Execution Traces: 3 (all verified)

**Anti-Hallucination Status**: ✅ **ALL CLAIMS VALIDATED**

---

## 🧭 SAE OPERATIONAL PLAYBOOK

### **Priority Answers (Top 5)**

#### **P1) Missing NGS – What do we show TODAY?**

**Policy**: Show proactive, deterministic guidance only. No SAE‑driven drug inferences until tumor data exists.

**TODAY deliverables for Ayesha**:
- SOC card (carboplatin + paclitaxel; bevacizumab rationale for ascites/peritoneal)
- Trials list (frontline, NYC) with transparent eligibility reasoning and confidence gates
- CA‑125 monitoring plan (cycle‑3 ≥70% drop, cycle‑6 ≥90%, target <35; resistance: on‑therapy rise or <50% at cycle‑3)
- Next‑test recommender (order of operations): 1) HRD (MyChoice/tissue), 2) ctDNA for MSI/TMB + somatic HRR, 3) SLFN11 IHC (PARP sensitivity), 4) ABCB1 proxy if prior taxane becomes relevant
- Mechanism Map: hidden (or grey "Awaiting NGS"). Hint tiles limited to test order, trials lever, monitoring; no "try/avoid" drug hints yet

---

#### **P2) SAE thresholds – source and policy**

**Bands not single points; avoid brittle hard gates.**

**Thresholds** (calibrated bands; use hysteresis ±0.05 to avoid flapping):
- **dna_repair_capacity**: high ≥0.70; moderate 0.40–0.69; low <0.40
- **pathway_burden.mapk/pi3k/vegf**: high ≥0.70; moderate 0.40–0.69; low <0.40
- **essentiality_signal**: high ≥0.80 (stricter); moderate 0.50–0.79
- **cross_resistance_risk**: high >0.70; moderate 0.40–0.70
- **cohort_overlap**: high ≥0.70; moderate 0.40–0.69; low <0.40

**Sources**: literature anchors (GOG‑218/ICON7, PAOLA‑1), internal calibration on retrospective cases, oncologist consensus. Treat as policy constants; log for future recalibration.

---

#### **P3) Gemini trial tagging – reliability policy**

**Offline only; never in runtime paths.**

**Validation protocol**:
- Batch tag 200 ovarian trials → human spot‑review 30 diverse trials
- Accept batch if ≥90% tag accuracy; otherwise adjust prompt taxonomy and re‑tag
- Persist `model`, `version`, `parsed_at`, `reviewed_by`, `source_checksum` with each record
- Update cadence: weekly diff for new/changed trials. Uncertain tags default to neutral vector; never force a mechanism label

---

#### **P4) Mechanism fit vs eligibility – tiebreak rules**

**Ranking**: score = eligibility α=0.7 + mechanism_fit β=0.3 (conservative weighting)

**Guardrails**:
- Minimum eligibility threshold to enter top‑10: ≥0.60
- Minimum mechanism_fit for mechanism‑gated display: ≥0.50; if <0.50, show but without mechanism boost and add "low mechanism fit" warning
- Never suppress SOC; SOC card remains first‑class
- Provide "Show all trials" toggle for clinician control

---

#### **P5) Hint tile language – tone policy**

**Use suggestive, RUO‑appropriate tone** (avoids paternalism; increases adoption):
- "Consider ordering HRD (impacts PARP eligibility)."
- "Consider PARP + bevacizumab (ascites/peritoneal)."
- "Consider avoiding re‑taxane (cross‑resistance risk)."

**Max 4 tiles**; priority order: Next test → Trials lever → Monitoring → Avoid (only if applicable). No "avoid" tile for treatment‑naive.

---

### **Claim‑Level Answers (Operationalized)**

#### **C1) DNA_repair_capacity high + ascites → platinum ± bevacizumab; PARP maintenance if HRD≥42; ATR/CHK1 on resistance**

**Feature definition**: dna_repair_capacity = 0.6×DDR_burden + 0.2×essentiality_signal (if HRR gene) + 0.2×exon_disruption (if pathogenic HRR variant present). Else fall back to DDR_burden.

**Banding behavior**: High ⇒ display clinician hint and allow modest trial boost for platinum ± bevacizumab arms (+0.10); moderate ⇒ hint only; low ⇒ no hint.

**Resistance detection**: trigger when any two of:
- HRD drop ≥10 points vs baseline
- dna_repair_capacity decrease ≥0.15 vs baseline
- CA‑125 <50% drop by cycle‑3 or on‑therapy rise

**TODAY (no NGS)**: Show "Awaiting HRD; consider ordering HRD to unlock PARP gating." No SAE‑driven drug confidence yet.

---

#### **C2) RAS/MAPK hotspot or high MAPK burden → MEK/RAF trial candidates; deprioritize MEK monotherapy if absent**

**Hotspot detection**: use COSMIC/hardcoded list (e.g., KRAS G12C/G12D/G12V, NRAS Q61, BRAF V600E). SAE `hotspot_mutation` may assist but cannot override COSMIC.

**Conflict policy**: hotspot present but MAPK burden low (<0.40) ⇒ show trials but no monotherapy boost; combos acceptable if other pathway rationale exists. Boost only if burden ≥0.40; full boost at ≥0.70.

**Deprioritize MEK monotherapy** when burden <0.40 (−0.15) and show caution copy.

**TODAY**: show "MAPK status: awaiting NGS"; do not surface MEK/RAF levers yet.

---

#### **C3) Essentiality high (DDR) → strengthens PARP case; HR restoration pattern → preemptive ATR/CHK1**

**essentiality_signal source**: Insights/dep‑map style dependency prior; treat as calibrated 0–1.

**Threshold**: high ≥0.80; effect: add badge, confidence lift cap +0.03 only (avoid over‑weighting single feature).

**Longitudinal logic**: need ≥2 timepoints. HR restoration if HRD drop ≥10 AND dna_repair_capacity drop ≥0.15 OR emergence of RAD51 reactivation signature. Immediate alert; does not wait for radiographic progression.

**For treatment‑naive**: show "No longitudinal signal yet; set baseline and re‑assess at week‑12/24."

---

#### **C4) Cross_resistance_risk high with prior taxane/ABCB1 → avoid substrates; propose non‑substrates**

**Risk model**: max(
- 0.8 if prior taxane with progression ≤6mo
- 0.7 if ABCB1 CNV>4 or expression proxy high
- else 0.3 baseline)

**ABCB1 inference before expression**: use CNV if available; otherwise UNKNOWN (do not infer).

**Substrate lists**: use PharmGKB/DrugBank curated classes; versioned; RUO.

**Non‑substrates**: platinum, PARP, ATR/CHK1/WEE1 (verify per‑agent substrate status; do not assume). Provide "likely non‑substrate" tag with source.

**TODAY (naive)**: show "Cross‑resistance: low/unknown; no avoidance guidance yet."

---

#### **C5) Cohort_overlap low + confidence low → push trials; high overlap → lean standard with modest lift**

**Definition**: overlap of patient phenotype with literature/trial cohorts (disease, line, key biomarkers); proxy until cohort DB exists.

**Computation policy**:
- High (≥0.70): disease + key biomarker archetype well‑represented (e.g., HRD‑high HGSOC). Add +0.05 confidence and badge
- Moderate (0.40–0.69): no lift, no "push trials" banner
- Low (<0.40): show "clinical trial recommended" banner; keep SOC but rank trials more prominently

**Without cohort DB**: use policy proxies and explicitly label as proxy.

---

#### **C6) Next‑test recommender (choose ONE first)**

**Trigger**: completeness L0/L1 or missing any of HRD/MSI/TMB.

**Priority order (Ayesha)**: 1) HRD (PARP gate), 2) ctDNA MSI/TMB + somatic HRR (IO and DDR combo considerations), 3) SLFN11 IHC (PARP sensitivity), 4) ABCB1 proxy if post‑taxane scenario emerges.

**Messaging detail**: use "differential branches" format (If positive → X; If negative → Y) with turnaround.

---

#### **C7) SAE‑aligned trial ranking (mechanism fit)**

**Vectors**:
- Patient `sae_mechanism_vector` = [DDR, MAPK, PI3K, VEGF, IO, Efflux] from SAE; L2‑normalize vectors before cosine
- Trial `moa_vector` from offline MoA tagging; store versioned; neutral if unknown

**Fallback**: if patient vector all zeros/unknown, mechanism_fit disabled (β=0) and explain "awaiting NGS; eligibility‑only ranking shown."

**Explanation**: show breakdown ("DDR 0.82 × PARP+ATR → 0.95 fit").

**Wrong MoA handling**: human review gate; uncertain trials remain neutral.

---

#### **C8) Clinician hint tiles (UI)**

**Max 4**; prioritize: Next test → Trials lever → Monitoring → Avoid (only when truly applicable).

**Pre‑NGS**: test + monitoring + trials lever only. Post‑NGS: enable "try next/avoid" based on SAE features.

**Copy tone**: suggestive; include short reasons; link to source or provenance.

---

#### **C9) Mechanism Map UI (chips)**

**Thresholds**: Green ≥0.70; Yellow 0.40–0.69; Gray <0.40.

**IO special**: Green if MSI‑H; Gray if unknown; Red if MSI‑S.

**Pre‑NGS**: show gray chips with "Awaiting NGS" overlay and tooltip clarifying meaning.

---

#### **C10) Pre‑computed care pathways**

**On‑demand assembly** (not batch). Criteria for "line‑ready ATR combo trials":
- Recruiting; Phase II/III; ≤50 miles; mechanism_fit ≥0.60; exclusions manageable

**Logistics factor**: multiply combined score by proximity factor (1.0 ≤10 miles; 0.9 ≤50; 0.7 >100). Never hide a close, good‑fit trial.

**UI**: by default collapse low‑fit mechanisms into "Explore more" with clear toggle to show all.

---

### **Alignment With Ayesha**

- **TODAY (no NGS)**: deliver SOC + trials + CA‑125 + Next‑test recommender; hide mechanism map; hints limited to testing/monitoring/logistics; no SAE‑based efficacy claims
- **WHEN HRD returns**: if ≥42, unlock PARP maintenance (with SAE rationale when available); if <42, surface ATR/CHK1 trials; keep RUO labels
- **IF resistance signals emerge**: switch path per C1/C3 and show Resistance Playbook tiles

---

### **Provenance & Safety**

- RUO labels on all hints; provenance logs include thresholds used, vectors, gating decisions, and data completeness level
- No runtime LLM calls in clinical paths; offline LLM outputs human‑reviewed and versioned
- All thresholds and policies are configurable constants; shipped with documentation and sources

**Status**: APPROVED POLICY. Proceed to implement per debrief, honoring these guardrails.

---

## 📋 ACTION ITEMS & NEXT STEPS

### **Immediate Actions (Next 2 Hours)**

1. **Verify Data Quality** ✅ **PARTIALLY COMPLETE**
   - ✅ Outcome field populated (53 sensitive, 11 refractory, 2 resistant)
   - ✅ Feature indices valid (all < 32768)
   - [ ] Check feature distributions (mean, std, variation)
   - [ ] Verify features vary across patients

2. **Test Modal Service** ✅ **MOSTLY COMPLETE**
   - ✅ Service operational: 66 patients extracted successfully
   - ✅ Trained weights loaded: evo2_7b migration complete
   - [ ] Test health check endpoint: `curl http://localhost:8000/api/sae/health`
   - [ ] Check environment variables: `SAE_SERVICE_URL`, `ENABLE_TRUE_SAE`

3. **Review Evo2 Notebook** ⏸️ **IN PROGRESS**
   - ✅ Layer name verified ("blocks.26" correct)
   - ✅ Architecture matches (BatchTopKTiedSAE)
   - [ ] Complete notebook review (1780 lines)
   - [ ] Document feature interpretation approach

---

### **Short-Term Actions (Next Week)**

4. **Define Validation Criteria** ⏸️ **PENDING**
   - [ ] Biomarker analysis success criteria
   - [ ] Pathway mapping validation strategy
   - [ ] End-to-end validation plan

5. **Re-Run Biomarker Analysis** ⏸️ **PENDING** (After Step 1 complete)
   - Run with verified data
   - Check results for significant features
   - Document findings

6. **Create Pathway Mapping Strategy** ⏸️ **PENDING** (After Step 5)
   - Determine approach (gene-based? feature-based?)
   - Create validation plan
   - Document uncertainty

---

### **Manager-Approved Priorities**

**Priority 0: Fix Classification Assessment (BLOCKER)**
- Inspect PFS_STATUS field format in dataset
- Check PFS_STATUS parsing logic in classification function
- Fix parsing bug (0 events AND 0 censored = impossible)
- **Timeline**: 2 days

**Priority 1: Investigate Weak Correlations (CRITICAL)**
- Run 50-100 patient test with **random sampling** (not just lowest mutations)
- Compare correlation with vs without TMB/HRD/MSI features
- Check if treatment type affects correlation
- **Timeline**: 2 weeks
- **Success Criteria**: Correlations improve to r > 0.3 (moderate) OR we understand why correlations are weak and have mitigation plan

**Priority 2: Complete 50-Patient Test**
- Install lifelines package: `pip install lifelines`
- Run 50-patient test with random sampling
- Validate survival metrics compute correctly
- **Timeline**: 3 days

---

### **Pathway Validation Roadmap - Day 1 Tasks**

**Pre-Flight Checks** (5 minutes):
- [ ] Verify 469-patient file exists: `data/validation/sae_cohort/tcga_ov_platinum_with_mutations.json`
- [ ] Verify file structure matches documented schema
- [ ] Verify all 469 patients have `platinum_response` field
- [ ] Verify all 469 patients have `raw_response_value` field

**Day 1 Task 1: TMB Computation** (30 minutes):
- [ ] Create script: `scripts/data_acquisition/compute_tmb.py`
- [ ] Implement formula: `tmb = num_mutations / 38.0`
- [ ] Add `tmb_score` to all 469 patients
- [ ] Categorize: TMB-Low (<6), TMB-Intermediate (6-10), TMB-High (≥10)
- [ ] Validate: Check TMB distribution (should be reasonable for ovarian cancer)

**Day 1 Task 2: Response Format Standardization** (30 minutes):
- [ ] Create script: `scripts/data_acquisition/standardize_response.py`
- [ ] Implement mapping function (from Q2 answer)
- [ ] Transform all 469 patients to required schema
- [ ] Validate: Check all patients have structured response format

**Day 1 Task 3: Field Renaming** (15 minutes):
- [ ] Rename `tcga_patient_id` → `patient_id`
- [ ] Rename `tcga_sample_id` → `sample_id`
- [ ] Verify no field name conflicts

**Day 1 Task 4: Output Generation** (15 minutes):
- [ ] Generate final JSON: `data/validation/tcga_ov_469_validated.json`
- [ ] Include summary statistics
- [ ] Include provenance (source, date, version)

**Total Day 1 Time**: ~90 minutes

---

## 📊 SUMMARY

### **Overall Alignment Score**: **85% ALIGNED** ✅

**Breakdown**:
- ✅ **Analysis & Question Answering**: 100% complete
- ✅ **Verification Layer**: 100% complementary (fills gaps)
- ⚠️ **Validation Assessment**: 0% complete (different focus: verification vs validation)
- ❌ **Documentation**: 0% complete (not in verification plan scope)

### **Critical Blockers**

1. **Feature→Pathway Mapping** ❌ **CRITICAL BLOCKER**
   - Blocks ALL THREE services from using TRUE SAE features
   - Current workaround: All services use PROXY features
   - Mitigation: Biomarker-driven mapping approach (pending analysis)

2. **Weak Correlations** ⚠️ **P0 BLOCKER**
   - PFS correlation: r=0.047 (negligible)
   - OS correlation: r=0.198 (weak)
   - System NOT ready for production until resolved

3. **Classification Assessment** ⚠️ **P0 BLOCKER**
   - Cannot assess (0 events - parsing bug)
   - Must fix before production deployment

### **Resolved Issues**

1. **Random SAE Weights** ✅ **RESOLVED**
   - Migrated to evo2_7b with trained weights
   - 66 patients extracted successfully
   - Feature extraction operational

2. **Modal Service Deployment** ✅ **MOSTLY RESOLVED**
   - Service operational: 66 patients extracted successfully
   - Circuit breaker implemented
   - Error handling exists

---

## 📁 CONSOLIDATED FROM

1. `PLAN_ALIGNMENT_ANALYSIS.md` - Plan alignment between comprehensive plan and verification layer
2. `PLAN_ITERATION_ADDITIONS.md` - Testing infrastructure, data sources, scope review, fail-safes
3. `PLAN_ITERATION_SUMMARY.md` - Master sources of truth summary
4. `PLAN_UNCERTAINTIES_AND_RISKS.md` - Critical uncertainties, gaps, failure points
5. `MANAGER_BENCHMARK_REVIEW.md` - Manager review of benchmark accuracy
6. `MANAGER_ANSWERS_REVIEW.md` - Review of manager answers for pathway validation
7. `MANAGER_REVIEW_PACKAGE.md` - Complete review package for manager approval
8. `MANAGER_ANSWERS_TO_ZO_SAE_QUESTIONS.md` - Authoritative SAE operational playbook

**All source documents archived to `.cursor/ayesha/archive/`**

---

**The righteous path: Plan thoroughly, validate continuously, execute with precision. Honor Manager's guardrails.**

